Children
Nevirapine (Viramune) is licensed in Europe and the United States for the treatment of HIV infection in infants and children. In children weighing more than 50kg, the adult dose is used. However, the drug is available in the form of a suspension for children under 16 years of age who weigh less than 50kg. The recommended doses are 4mg/kg once daily for the first two weeks, followed by 7mg/kg twice daily for children under eight years, or 4mg/kg twice daily for children aged eight and over.
Nevirapine appears to be safe, effective and well tolerated in children from birth, although no large, randomised studies comparing a nevirapine-based regimen to other triple regimens have been reported[1][2]. Side-effects are similar in children and adults[3].
latest aidsmap news
- Large HIV vaccine study will not go ahead
- Swiss court rules all people with HIV can be criminally liable for transmission, even if untested
- Genital shedding of HIV in women with undetectable viral load: less of it, but still happening
- Microbicides could prevent more infections in men than in women
- Knowledge of STIs poor in rural Tanzania - associated with risky sex and infection with HIV
- HIV treatment effective for infants in resource-limited settings
- Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear
- One third of people with HIV have experienced sexual difficulties in the past month
- Differing causes of lung infections in HIV-positive patients: implications for diagnosis and treatment
- Roche to halt HIV drug research